Science&Humans Secures CAD $10M Series A Led by Pender Ventures and WELL Health

Science&Humans, a Toronto-based hormone health platform, has closed an oversubscribed CAD $10M Series A financing round, combining equity and debt. The round was led by Pender Ventures, with participation from WELL Health Technologies Corp., entrepreneur Michele Romanow, CIBC Innovation Banking, and a group of U.S.-based healthcare investors and physicians. The raise represents approximately USD $7M and marks a significant milestone for the company as it continues to scale hormone care services across Canada.

Founded by Hira Siddiqui and Aftab Pashaw, Science&Humans provides hormone-focused care for conditions including polycystic ovary syndrome (PCOS), premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), endometriosis, fertility challenges, perimenopause, menopause, and andropause. The company operates through both direct-to-consumer offerings and employer-sponsored wellness programs, positioning its platform at the intersection of clinical care and workplace health. Science&Humans reports it has served more than 50,000 patients nationwide, with over 80% reporting symptom improvement within 90 days, according to company data.

Aftab Pashaw, co-founder and CEO, highlighted the evolving perception of hormone health in Canada, stating, “Hormone health was not treated as a category in Canada when we started. This funding reflects a broader shift in how healthcare systems, employers, and patients are thinking about daily wellness, mental health, and long-term outcomes.” Investors have echoed this view, framing hormone health as an emerging priority within healthcare delivery and benefits design.

Michele Romanow described the category’s trajectory by saying, “Hormone health is moving into the mainstream in much the same way mental health did a decade ago.” She added, “What Science&Humans has built is a scalable, clinically grounded approach to an area of healthcare that has long been underserved, despite its profound impact on people’s lives and economic participation.”

From an investment perspective, Pender Ventures pointed to the company’s operating model as a key differentiator. “Science&Humans has built a differentiated, evidence-based platform for hormone care—an area that has been historically underdiagnosed and underserved,” said Meryeme Lahmami, principal at Pender Ventures. “Their vertically integrated model enables consistent, high-quality care at scale through employers and insurers, positioning the company well as demand for hormone health solutions continues to grow.”

The newly raised capital will be used to expand Science&Humans’ technology and clinical platform, increase access across Canada, and deepen relationships with employers and insurers as demand for hormone health services continues to rise.

Click here for the original news story.